CBS - The 17th Left Main & Coronary Bifurcation Summit, CBS2025

HOME
CBS 2019
At CBS

General Information

Left Main & Coronary Bifurcation Summit (CBS) was founded in 2006 as a think tank dedicated to the treatment of left main and coronary bifurcation lesions. CBS aims to improve cardiological care by refreshing fundamental researches, clinical trials, yearly published guidelines, emerged ideas and case-based discussion.

Association and Affiliations
- Organized by
  
  Nanjing Heart Center
  
  Asian Bifurcation Club (ABC)
  
  Nanjing First Hospital, Nanjing Medical University
- Co-organized by
  
  Chinese Society of Cardiology (CSC)
  
  Capacity Building and Continuing Education Center,National Health and Family Planning Commission (CBCEC)
  
  American Society for Cardiovascular Angiography and Interventions (SCAI)
  
  Asian Heart Society (AHS)
Contact Us
- Registration Administration of Domestic Representatives
  
  Hongjuan Peng : +86-13913895477
  
  Haimei Xu +86-13914736846
  
  cbsnj@cbsmd.cn
- Registration Administration of Overseas Representatives
  
  Ling Lin : +86 (25) 52271398
  
  +86-13951884596
  
  cbs@cbsmd.cn
- Management of Challenging Cases
  
  Yingying Zhao :+86-13815408517
  
  sub@cbsmd.cn
Address

CBS2019 Congress Secretariat, Nanjing First Hospital, Building No.9 68# Changle Road, Nanjing, China

210006
FACULTY
FACULTY

General Chairman
Congress Chairman
Course Directors International Faculty Domestic Faculty Hong Kong and Taiwan Faculty Members of Academic Committee
Education Center

Education Center

• Online Education (For more customized user interface with self-defined collection of research papers and education resources.)

• CBS Education Resource

• CBSMD Scientific Library
SCIENTIFIC LIBRARY

SCIENTIFIC LIBRARY

Research Paper

> Acute Coronary Syndrom

> ASCVD Prevention

> Bifurcation Stenting

> Cardio-Oncology

> Congestive Heart Failure

> DAPT Duration

> Drug Coated Balloon

> Fractional Flow Reserve

> IVUS Guidance

> Optical Coherence Tomography

> Pulmonary Hypertension

> Rotational Atherectomy

> Shear Stress

> Stenting Left Main

> Transcatheter Aortic Valve Replacement

> Percutaneous LAA Occlusion

> Mitral/Tricuspid Valvular Disease

> Other Relevant Articles

Recommended Paper

Management of Acute Myocardial Infarction During the COVID-19 Pandemic

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19)

急性冠脉综合征

Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR) The Wait for High-Sensitivity Troponin Is Over—Proceed Cautiously Impact of the US Food and Drug Administration–Approved Sex-Specific Cutoff Values for High-Sensitivity Cardiac Troponin T to Diagnose Myocardial Infarction Revision: prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shock-a substudy of the IABP-SHOCK II-trial Improvement of Clinical Outcome in Patients With ST-Elevation Myocardial Infarction Between 1999 And 2016 in China : The Prospective, Multicenter Registry MOODY Study Prognostic Significance of Complex Ventricular Arrhythmias Complicating ST-Segment Elevation Myocardial Infarction What's new in the Fourth Universal Definition of Myocardial infarction? Respiratory syncytial virus infection and risk of acute myocardial infarction

Sort by hits |<< 1 2 3 4 5 6 7 ...>>|

Original Research2020 Jul 15;S0167-5273(20)33449-5.

JOURNAL：Int J Cardiol. Article Link

The prognostic role of mid-range ejection fraction in ST-segment elevation myocardial infarction

M Alkhalil, A Kearney, D MacElhatton et al. Keywords: mid-range ejection fraction; STEMI; suboptimal medical therapy; renal dysfunction

ABSTRACT

OBJECIVE - There is a paucity of studies investigating the impact of mid-range ejection fraction (mrEF) on clinical outcomes, including ventricular arrhythmias, in ST-segment-elevation myocardial infarction (STEMI). We sought to investigate the prognostic role of mrEF post STEMI and whether recommended medical therapy may modify future risk.

METHODS - 533 consecutive patients from a single large-volume centre who underwent primary percutaneous coronary intervention were included. Reduced EF (<40%), mrEF (40-49%) and preserved EF (≥50%) were defined according to the European Society of Cardiology guidelines. Clinical outcomes were prospectively collected, and the primary endpoint was defined as the composite of death, re-admission with heart failure, sustained ventricular arrhythmia requiring hospitalisation or implantable cardioverter defibrillator over three years follow-up.

RESULTS - There was a stepwise increase in the primary endpoint according to EF group (8%, 17%, 30%, P < .001), which was derived from each individual component. Compared to preserved EF, patients with mrEF had significantly higher risk [HR 4.08 (95%CI 2.38 to 6.99), P < .001]. The use of suboptimal medical therapy was associated with increased future risk, particularly in mrEF [HR 2.62, (95%CI 1.18 to 5.83), P = .018]. The proportion of mrEF patients who experience the primary endpoint was significantly different according the status of kidney function and recommended medical therapy (8%, 20%, 33%, 50%, P < .001).

CONCLUSIONS - Patients presenting with mrEF following STEMI had increased risk of death, heart failure hospitalisation and ventricular arrhythmias compared to preserved EF. Suboptimal medical therapy in mrEF was associated with increased adverse events, particularly in patients with renal dysfunction.

Abstract

Recommended Article

The prognostic role of mid-range ejection fraction in ST-segment elevation myocardial infarction

ABSTRACT